{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:33:05Z","timestamp":1787020385097,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated with this drug may develop candidiasis. This report presents a case of atypical oral candidiasis occurring during targeted drug immunotherapy with an interleukin 17 (IL-17) inhibitor (secukinumab), with the aim of emphasisinge the necessity of periodical oral health assessment and monitoring. It provides a rational clinical approach to therapeutic protocol in the treatment of side effects associated with novel medications for autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Symptomatic tongue lesions were observed in a 50-year-old female patient on a monthly systemic treatment of 300\u00a0mg of secukinumab, which appeared after 60\u00a0days of using the medication. Two inconclusive biopsies and an unsuccessful application of oral corticosteroids made the diagnostic process challenging. Papillae on the back of the tongue were atrophied, forming a well-defined erythema and white non-detachable plaques on the lateral border of the tongue. Cytopathological and histopathological exam results were compatible with a diagnosis of oral candidiasis. Topical antifungal medication led to subsequent regression of the tongue lesions. During asymptomatic period and follow up for 7\u00a0months, a reduced monthly dose 150\u00a0mg of secukinumab was administered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients undergoing treatment with IL-17 blockers, such as secukinumab, should be carefully monitored in order to avoid oral side effects resulting from the use of this medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12903-021-01653-6","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T05:05:30Z","timestamp":1623128730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-1785","authenticated-orcid":false,"given":"Bruna Lavinas Sayed","family":"Picciani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Dziedzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Trist\u00e3o","family":"Werneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello Alves","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaylla N\u00fa\u00f1ez Amin","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nara Regina","family":"Quintanilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane Pedra","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"1653_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/0019-5154.156315","volume":"60","author":"S Gupta","year":"2015","unstructured":"Gupta S, Jawanda MK. Oral Lichen planus: an update on etiology, pathogenesis, clinical presentation, diagnosis and management. Indian J Dermatol. 2015;60:222\u20139.","journal-title":"Indian J Dermatol"},{"key":"1653_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/BOR.0000000000000274","volume":"28","author":"CT Ritchlin","year":"2016","unstructured":"Ritchlin CT, Krueger JG. New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016;28:204\u201310.","journal-title":"Curr Opin Rheumatol"},{"key":"1653_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20081463","volume":"206","author":"HR Conti","year":"2009","unstructured":"Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299\u2013311.","journal-title":"J Exp Med"},{"key":"1653_CR4","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/eji.201242605","volume":"42","author":"S Cypowyj","year":"2012","unstructured":"Cypowyj S, Picard C, Marodi L, Casanova JL, Puel A. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol. 2012;42:2246\u201354.","journal-title":"Eur J Immunol"},{"key":"1653_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338.","journal-title":"N Engl J Med"},{"key":"1653_CR6","doi-asserted-by":"publisher","first-page":"103575","DOI":"10.1016\/j.micpath.2019.103575","volume":"134","author":"L Hua","year":"2019","unstructured":"Hua L, Heb C, Zhao C, Chen X, Hua H, Yan Z, et al. Characterization of oral candidiasis and the Candida species profile in patients with oral mucosal diseases. Microb Pathog. 2019;134:103575.","journal-title":"Microb Pathog"},{"key":"1653_CR7","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.3390\/nu11102449","volume":"11","author":"T Mundula","year":"2019","unstructured":"Mundula T, Ricci F, Barbetta B, Baccini M, Amedei A. Effect of probiotics on oral candidiasis: a systematic review and meta-analysis. Nutrients. 2019;11:2449.","journal-title":"Nutrients"},{"key":"1653_CR8","first-page":"352","volume":"5","author":"CML Padilha","year":"2014","unstructured":"Padilha CML, Picciani BLS, Santos BM, Silva-Junior A, Dias EP. Comparative analysis of Gram\u2019s method and PAS for the identification of Candida spp. samples from the oral mucosa. J Bras Patol Med Lab. 2014;5:352\u20138.","journal-title":"J Bras Patol Med Lab"},{"key":"1653_CR9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jaad.2012.11.033","volume":"68","author":"BL Picciani","year":"2013","unstructured":"Picciani BL, Michalski-Santos B, Carneiro S, Sampaio AL, Avelleira JCR, Azulay DR, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol. 2013;68:986\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"1653_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09546634.2018.1530437","volume":"29","author":"M Papini","year":"2018","unstructured":"Papini M, Natalini Y. Candida infections in psoriatic patients on anti-IL17 therapy: a case series. J Dermatolog Treat. 2018;29:3\u20134.","journal-title":"J Dermatolog Treat"},{"key":"1653_CR11","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1111\/1346-8138.13637","volume":"44","author":"T Komori","year":"2017","unstructured":"Komori T, Honda T, Endo Y, Kaku Y, Otsuka A, Kabashima K. Oral lichen planus associated with candidiasis during secukinumab treatment. J Dermatol. 2017;44:e60\u20131.","journal-title":"J Dermatol"},{"key":"1653_CR12","doi-asserted-by":"crossref","unstructured":"Farah CS. Concurrent chronic hyperplastic candidosis and oral lichenoid lesion as adverse events of secukinumab therapy. Aust Dent J. 2021; Online ahead of print.","DOI":"10.1111\/adj.12833"},{"key":"1653_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4049\/jimmunol.1500909","volume":"195","author":"HR Conti","year":"2015","unstructured":"Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195:780\u20138.","journal-title":"J Immunol"},{"key":"1653_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.15015","volume":"177","author":"D Saunte","year":"2017","unstructured":"Saunte D, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47\u201362.","journal-title":"Br J Dermatol"},{"key":"1653_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484\u201393.","journal-title":"Br J Dermatol"},{"issue":"60","key":"1653_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2334\/josnusd.16-0702","volume":"24","author":"O Kujan","year":"2018","unstructured":"Kujan O, Pemberton MN, Schwarz M, Sloan P. Evaluation of an innovative oral brush for potential applications using liquid based cytology. J Oral Sci. 2018;24(60):45\u201350.","journal-title":"J Oral Sci"},{"key":"1653_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjd.13814","volume":"173","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Humeniuk J, Frambach Y, Bissonnette R, Goodman J, Shevade S, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173:777\u201387.","journal-title":"Br J Dermatol"},{"key":"1653_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, Heijde D, et al. Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329\u201339.","journal-title":"N Engl J Med"},{"key":"1653_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"key":"1653_CR20","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jaad.2014.08.039","volume":"71","author":"K Papp","year":"2014","unstructured":"Papp K, Leonardi C, Menter A, Kavanaugh A, Ritchlin CT, Rahmanet P, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71:e3.","journal-title":"J Am Acad Dermatol"},{"key":"1653_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2015","unstructured":"Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2015;81:44\u201352.","journal-title":"J Dermatol Sci"},{"key":"1653_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741\u201351.","journal-title":"Br J Dermatol"},{"key":"1653_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345\u201356.","journal-title":"N Engl J Med"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-021-01653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-021-01653-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-021-01653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T05:08:01Z","timestamp":1623128881000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-021-01653-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1653"],"URL":"https:\/\/doi.org\/10.1186\/s12903-021-01653-6","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of the School of Medicine, Universidade Federal Fluminense (95988618.9.1001.5243). The written consent was obtained from the patient in this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient signed an Informed Consent Form agreeing with the publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}